Only 3.1% of insulin-treated patients had an investigator-reported adverse event related to hypoglycemia and these patients accounted for only 5 MACE events; however, some hypoglycemic events may not have been reported and may have contributed to a higher rate of MACE in insulin-treated patients. The gene discussed is INS; the disease is Hypoglycemia.